NIH's Role In Sustaining the U.S. Economy | 2023 Update Now Available
Announcing Research 101 | UMR Answers Common Questions About NIH Research in this New Fact Sheet Series
Read UMR's Dec. 8 Letter to Congressional Leadership on the Urgent Need to Pass an FY23 Omnibus Appropriations Bill
Why Invest in NIH Research? | UMR Offers Fact Sheets Explaining Why Congress Must #keepNIHstrong

A participant in the NIH 2019-2020 Medical Research Scholars Program.

Photo Credit: National Institutes of Health

About This Photo

NIH tests therapies to help cut hospital stays for COVID-19 patients

The U.S. National Institutes of Health (NIH) has started a late-stage trial to evaluate if immune-modulating therapies from three drugmakers can help reduce the need for ventilators for COVID-19 patients and shorten their hospital stay. The NIH said on Friday it has selected three agents for the study – Johnson & Johnson, Janssen Research’s Remicade, Bristol Myers Squibb’s Orencia and Abbvie Inc’s experimental drug cenicriviroc.